linjc16/ctgov huggingface dataset:
Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry

Study Overview
=================
Brief Summary
-----------------
We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis, looking for unique protein signatures.

Detailed Description
-----------------
We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis. Data from different brain tissues including tumors of different histological sub-types will be analyzed for unique protein signatures. These protein signatures will then be statistically correlated with clinical data including time to tumor progression and response to therapy. The goal of this study is to determine molecular patterns that will be more predictive of tumor behavior, thus leading to an improved understanding of the basic biology of these poorly understood cancers. This in turn, may lead to more refined therapies and improved outcomes.

Official Title
-----------------
Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry

Conditions
-----------------
Brain Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A diagnosis of brain tumor or other non-cancerous tissue and are considered candidates fro a surgical procedure to biopsy or remove the brain tumor or other tissue type at Vanderbilt University Medical Center. Age 2 to 85 Exclusion Criteria: Patient or guardian that is unable to understand the informed consent process.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of proteomic signatures in brain tumor samples | measurement of proteomic signatures in brain tumor samples for unique protein signatures | immediately upon analysis of the sample |
Comparison Imaging System Between Spatially Modulated Quantitative Spectroscopy and Skin Spect Dermoscopy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to obtain skin spectroscopic data from two imaging systems. Comparison groups: Skin Spect dermoscope Spatially modulated quantitative spectrometer

Detailed Description
-----------------
The researcher can compare the spectroscopic data from the two systems as well as the relative concentrations of melanin, oxy- and deoxy- hemoglobin calculated from the measurements. Skin Spect can measure larger area of skin, whereas Spatially modulated quantitative spectrometer is a point-based measurement.Therefore, larger nevi will require multiple Spatially modulated quantitative spectrometer measurements for comparison with corresponding sub-regions of the larger Skin Spect measurements. Only sub-regions of the image data from Skin Spect that match the locations Spatially modulated quantitative spectrometer acquired data will be used in this correlation study. This researcher ensure that the spectral data collected by the two instruments are collected from the same spatial locations, should lesion heterogeneity be present.

Official Title
-----------------
Spectral Comparison Between Spatially Modulated Quantitative Spectroscopy and Polarization-Sensitive Hyperspectral Multimode Dermoscopy for the Purpose of Skin Compositional Analysis

Conditions
-----------------
Melanocytic Nevus

Intervention / Treatment
-----------------
* Device: Skin Spect dermoscope
* Device: Spatially modulated quantitative


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Skin lesion a mole located on flat surface of the body Exclusion Criteria: Mole located on complex surface Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Skin Spect dermoscope<br>Skin mole | Device: Skin Spect dermoscope<br>* Skin imaging<br>|
| Spatially modulated quantitative<br>Skin mole | Device: Spatially modulated quantitative<br>* Skin imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in human skin structure | Comparison Imaging Changes in human skin structure Between Spatially Modulated Quantitative Spectroscopy and Skin Spect Dermoscopy | up to 12 weeks |
The Ability of Peripheral Perfusion Index To Detect Changes of Hemodynamics in Patients With Pacemaker

Study Overview
=================
Brief Summary
-----------------
Pacemakers are widely used in postcardiotomy patients to avoid severe arrhythmia. The peripheral perfusion index (PI) has been considered as an effective parameter evaluating the circulation. In this study, investigators aim to avaluate the ability of peripheral perfusion index to detect changes of hemodynamics in postcardiotomy patients with pacemakers.

Detailed Description
-----------------
Pacemakers are widely used in postcardiotomy patients to avoid severe arrhythmia. The peripheral perfusion index (PI) has been considered as an effective parameter evaluating the circulation. In this study, investigators aim to evaluate the ability of peripheral perfusion index to detect changes of hemodynamics (cardiac output or storke volume,et al) in postcardiotomy patients with pacemakers.

Official Title
-----------------
The Ability of Peripheral Perfusion Index To Detect Changes of Hemodynamics in Patients With Pacemaker：a Prospective Study

Conditions
-----------------
Pacemaker Dependence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >=18 years old; postcardiotomy placement of temportary pacemaker during the surgery dependence of pacemaker (abscence of autonomic cardiac rhythm） Exclusion Criteria: hemodynamic unstable （high dose of vasoactive drugs） fingers ischemia, cannot monitor the peripheral perfusion index

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pacemaker dependent patients after cardiac surgery<br>Pacemakers are widely used in cardiotomy patients, while it's common that the patients happen to be pacemaker dependent. When the doctor decides to set the heart rate of the pacemaker, we record the hemodynamic parameters and peripheral perfusion index from 70-80-90-100-110 bpm. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac output | Measurement of cardiac output by Flotrac ,the metric is L/min. | During the study procedure | 
| stroke volume | Measurement of stroke volume by Flotrac ,the metric is ml. | During the study procedure | 
| Peripheral perfusion index | Measurement of Peripheral perfusion index by masimo radical. | During the study procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peripheral perfusion index, cardiac output, stroke volume
HPV Prevalence in 16-20 Year Old Males

Study Overview
=================
Brief Summary
-----------------
In Quebec, 18 birth cohorts of girls were vaccinated against HPV (aged 9 to 29 years in 2020). With an observed vaccination coverage of >80% an important herd effect might be expected. This study aim is to measure the HPV types prevalence in unvaccinated sexually active boys aged 16 to 20 years.

Detailed Description
-----------------
An HPV immunization program is in place in Quebec since 2008. By 2020 18 birth cohorts of girls were eligible for vaccination. Vaccine uptake with at least one dose of vaccine was >80%. With such a high vaccine uptake an important herd immunity might be expected. The main objective of this study is to measure the prevalence of different HPV types in unvaccinated sexually active boys aged 16 to 20 years. This is a cross sectional study which includes one visit for all participants. Self sampling technic is used. During this phase of the study a total of 681 boys will be recruited. An additional phase of the study will be conducted at the condition that the prevalence of HPV6/11/16/18/31/33/45/52 and 58 in unvaccinated boys will be at least 8.65%. The second phase of the study if conducted will measure the prevalence of the same HPV types in 681 vaccinated boys of the same age.

Official Title
-----------------
Evaluation of the Impact of Quebec HPV Immunization Program: Prevalence of HPV Types in 16-20 Year Old Males

Conditions
-----------------
HPV Infection

Intervention / Treatment
-----------------
* Other: Measurement of HPV types prevalence


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: unvaccinated against HPV sexually active Exclusion Criteria: received an HPV vaccine non sexually active

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Unvaccinated against HPV boys<br>Sexually active unvaccinated against HPV 16-20 years old boys. | Other: Measurement of HPV types prevalence<br>* Self collected genital samples to be tested for the presence of different HPV types.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of HPV 6/11/16/18/31/33/45/52 and 58 | Unvaccinated sexually active 16-20 year old boys will be tested | Up to 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of 31 HPV types | Unvaccinated sexually active 16-20 year old boys will be tested | Up to 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevalence, Boys
Patients Understanding of PROM Graphs

Study Overview
=================
Brief Summary
-----------------
This study evaluates patients' ability to understand PROM scores when presented in graphs. One half will receive one version of the survey, while the other half will receive a second version of the survey.

Official Title
-----------------
Patients Understanding of PROM Graphs: a Randomized Controlled Trial

Conditions
-----------------
Orthopedic Disorder

Intervention / Treatment
-----------------
* Other: survey 1
* Other: survey 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient at Stanford Clinics orthopaedic condition Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: line graph<br> | Other: survey 1<br>* survey with one version of depiction<br>|
| Active Comparator: bar graph<br> | Other: survey 2<br>* survey with one version of depiction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge test | Knowledge test questionnaire assessing the ability to understand the information the graphs. scored 0-100% correct | immediately after completing survey |
The Effect of Infliximab on Sperm Quality

Study Overview
=================
Brief Summary
-----------------
Background: The treatment of inflammatory bowel diseases (IBD) is based mainly on 3 compounds: 1- 5 aminosalysilates . 2- immunomodulators (Azathioprines). 3- Biologic therapies (Infliximab, Adalimumab) . There are no established data in the literature whether these therapies effects sperm quality. Given that a large number of the patients are young men in the reproductive stage of their lives , It of importance to investigate these effect. Aim: To investigate the effect of chronic treatment of any of the three therapy mentioned above, on sperm quality .

Official Title
-----------------
The Effect of Infliximab,Adalimumab, Azathioprines and 5-Aminosalicylate on Semen Quality in Men With Inflammatory Bowel Disease

Conditions
-----------------
Crohn's Disease, Ulcerative Colitis

Intervention / Treatment
-----------------
* Other: sperm quality test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male above the age of 18 Capable of giving informed consent Diagnosed with IBD at least 3 months Patients that are going to start a treatment with on of the following groups: 5ASA, Azathioprines, infliximab or ADAlimumab Patients that are treated with therapies mentioned in article 4 for at least 3 months Exclusion Criteria: Male younger than 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 2<br>patients healthy volunteers | Other: sperm quality test<br>* All participants will undergo sequential sperm quality tests and blood tests<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism in China

Study Overview
=================
Brief Summary
-----------------
Chronic obstructive pulmonary disease (COPD) is closely related to venous thromboembolism (VTE). But it is difficult to identify VTE in COPD patients in clinical practice. Therefore, the prevalence data of PTE in COPD is limited. Pulmonary thromboembolism (PTE) is an important factor effecting patients outcomes, but existing researches only have short follow-up time less than 1 year. This study aim to develop an early detection system of PTE in COPD and explore the disease course and prognosis.

Official Title
-----------------
The Study of Early Detection, Disease Course and Prognosis of Pulmonary Thromboembolism in Chronic Pulmonary Hypertension

Conditions
-----------------
COPD, PTE - Pulmonary Thromboembolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients hospitalized for chronic obstructive pulmonary disease (COPD) exacerbation Exclusion Criteria: Stable COPD patients COPD hospitalized for definite causes other than pulmonary thromboembolism Patients with malignant tumor Patients with contraindications for CT pulmonary angiography Psychopath

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | mortality in % | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COPD exacerbations | Total times | 3 years | 
| venous thromboembolism recurrence | total times | 3 years | 
| major bleeding | total times | 3 years |
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta cell function in children and adolescents with type 1 diabetes with a diabetes duration less than 18 months at intervention.

Official Title
-----------------
A Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Drug: rhGAD65 formulated in Alhydrogel® (Diamyd®)


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Male and female patients between 10 and 18 years of age, diagnosed with type 1 diabetes within 18 months Fasting C-peptide level above 0.1 nmol/l Presence of GAD65 antibodies Written informed consent (patient and parent/guardian) Key Exclusion Criteria: Secondary diabetes mellitus or MODY Treatment with immunosuppressants Treatment with any vaccine within 1 month prior to first Diamyd® dose or planned treatment with vaccine up to 2 months after the second Diamyd® dose Participation in other clinical trials with a new chemical entity within the previous 3 months History of certain diseases or conditions (e.g. epilepsy, anaemia, alcohole or drug abuse) HIV or hepatitis Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study Pregnancy (or planned pregnancy within one year after 2nd administration)

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: rhGAD65 formulated in Alhydrogel® (Diamyd®)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the efficacy of Diamyd® 20ug versus placebo with respect to preserving residual insulin secretion as measured by C-peptide levels. The effect of intervention will be evaluated at month 15 (main study period) and at month 30 (Extension phase). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety of Diamyd® 20ug. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 1 diabetes, GAD65, Autoimmunity, C-peptide, Children
Human Beta-defensin 1 in Vitiligo

Study Overview
=================
Brief Summary
-----------------
There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.

Official Title
-----------------
Estimation of Tissue Level of Human Beta-defensin 1 (HBD-1) in Vitiligo Before and After Narrowband UVB Phototherapy: a Case-control Study

Conditions
-----------------
Vitiligo

Intervention / Treatment
-----------------
* Other: skin biopsy before and after NB-UVB phototherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with non-segmental vitiligo. Both genders. Age more than 18 years old. New cases or cases not receiving any treatment for at least 3 months prior to the study. Exclusion Criteria: Universal or segmental vitiligo. Any contraindication to phototherapy treatment. History of autoimmune diseases or other systemic diseases. Any other skin disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: vitiligo patients<br>Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy | Other: skin biopsy before and after NB-UVB phototherapy<br>* skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1<br>|
| Active Comparator: Healthy controls<br>Tissue levels of human beta-defensin 1 in healthy controls | Other: skin biopsy before and after NB-UVB phototherapy<br>* skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy |  | 6 months to 1 year |